Facioscapulohumeral Muscular Dystrophy Clinical Trial
Official title:
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies.
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies, and to additionally explore the pharmacokinetics and biologic activity of ATYR1940 in adult participants with molecularly defined genetic muscular dystrophies. Participants who successfully complete the parent study (NCT02239224) are eligible for enrollment into this long-term extension study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00082108 -
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
|
||
Completed |
NCT02579239 -
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 1/Phase 2 | |
Terminated |
NCT02927080 -
Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 2 | |
Completed |
NCT02625662 -
Facioscapulohumeral Dystrophy in Children
|
||
Recruiting |
NCT04001582 -
The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry
|
||
Recruiting |
NCT06425445 -
Quantitative Assessment of Orofacial Muscle Function in FSHD
|
N/A | |
Terminated |
NCT03943290 -
Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
|
Phase 2 | |
Completed |
NCT01596803 -
Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD)
|
N/A | |
Active, not recruiting |
NCT03458832 -
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
|
||
Completed |
NCT02766985 -
Rasch-analysis of Clinical Severity in FSHD
|
||
Active, not recruiting |
NCT01671865 -
Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy
|
||
Completed |
NCT02413190 -
Bone Health in Facioscapulohumeral Muscular Dystrophy
|
||
Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
Completed |
NCT01437345 -
A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD
|
N/A | |
Completed |
NCT02836418 -
Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06086548 -
Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics
|
||
Completed |
NCT00821548 -
Electrostimulation of Shoulder Girdle and Quadriceps Muscles in Facioscapulohumeral Muscular Dystrophy Patients
|
N/A | |
Completed |
NCT05178706 -
Effectiveness of Upper Extremity Rehabilitation in pwFSHD (Patient With Facioscapulohumeral Dystrophia)
|
||
Completed |
NCT00104078 -
Study Evaluating MYO-029 in Adult Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05019625 -
Biomarker Development for Muscular Dystrophies
|